thor-2 cohort 3 interim analysis: erdafitinib in intermediate-risk nmibc with fgfr3/2 alterations
Published 1 year ago • 133 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
5:14
erdafitinib demonstrates efficacy in intermediate-risk nmibc with fgfr alterations
-
3:37
phase iii thor study: erdafitinib vs. pembrolizumab in fgfr-altered advanced or metastatic uc
-
1:49
thor: impact of fgfr3 alterations in muc on subtype and outcomes with erdafitinib vs pembrolizumab
-
1:47
thor: erdafitinib in metastatic urothelial cancer with fgfr alterations
-
1:04
thor: erdafitinib in advanced or metastatic urothelial cancer and fgfr alterations
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer
-
5:31
tamm-horsfall protein (uromodulin) - urine casts - kidney function tests - labs
-
10:21
the pros and cons of proton therapy | mark scholz, md | pcri
-
26:20
management of non-muscle invasive bladder cancer
-
2:15
tar-210 erdafitinib intravesical delivery system in non-muscle invasive bladder cancer
-
4:51
expert video report on the management of patients with high-risk non-muscle invasive bladder cancer
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
2:31
an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
-
2:23
envision: ugn-102 and chemoablation for low-grade, intermediate-risk nmibc
-
0:18
journey through the arteries: life’s vital highways #3danatomy
-
5:24
case 3: fgfr-targeted therapy adverse events in bladder cancer
-
1:12
scott tagawa, md, on the study investigating nadofaragene firadenovec in bcg unresponsive nmibc
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
4:28
very high risk non-muscle-invasive bladder cancer (nmibc) in the current landscape of nmibc
-
6:49
the evolving landscape in the management of high-risk non-muscle-invasive bladder cancer
-
4:36
an overview of gleason 3 4 & gleason 4 3 prostate cancer | ask a prostate expert, mark scholz, md